INFLIXIMAB TREATMENT IN IBD: FROM THEORY TO CLINICAL PRACTICE

sabato 19 settembre 2020

Biosimilars are increasingly used to treat ibd patients. Subcutaneous infliximab is now available in IBD.

As intra venous infliximab can be used for every ibd patient refractory to standard treatment its sub cut formulation could be a game changer in routine practice.

per info segreteria@materia1a.it | +39 0363 1848776

Speaker
Prof. Silvio Danese - Prof. Laurent Peyrin-Biroulet - Stefan Schreiber